|
Myxopapillary ependymoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes.
|
26075792 |
2015 |
|
Anaplastic Ependymoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes.
|
26075792 |
2015 |
|
Papillary ependymoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes.
|
26075792 |
2015 |
|
Cellular Ependymoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes.
|
26075792 |
2015 |
|
Adenocarcinoma of prostate
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Colorectal Neoplasms
|
0.190 |
PosttranslationalModification
|
group |
BEFREE |
TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors.
|
25239454 |
2014 |
|
Colorectal Neoplasms
|
0.190 |
AlteredExpression
|
group |
BEFREE |
The receptor tyrosine kinase EphB2 is expressed by colon progenitor cells; however, only 39% of colorectal tumors express EphB2 and expression levels decline with disease progression.
|
19366806 |
2009 |
|
Colorectal Neoplasms
|
0.190 |
AlteredExpression
|
group |
LHGDN |
Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer.
|
18695888 |
2008 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
LHGDN |
Germline EPHB2 receptor variants in familial colorectal cancer.
|
18682749 |
2008 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
CLINVAR |
Germline EPHB2 receptor variants in familial colorectal cancer.
|
18682749 |
2008 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
BEFREE |
Inactivation of EPHB2 has recently been shown to accelerate tumorigenesis in the colon and rectum, and we have previously demonstrated frequent frameshift mutations (41%) in an A9 coding microsatellite repeat in exon 17 of EPHB2 in colorectal tumors with microsatellite instability (MSI).
|
16819508 |
2007 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
LHGDN |
We detected novel germline EPHB2 alterations in patients with colorectal tumors.
|
16740153 |
2006 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
BEFREE |
We detected novel germline EPHB2 alterations in patients with colorectal tumors.
|
16740153 |
2006 |
|
Colorectal Neoplasms
|
0.190 |
PosttranslationalModification
|
group |
BEFREE |
In conclusion, in this study, we elucidate the molecular mechanisms of inactivation of EPHB2 and show for the first time the high incidence of frameshift mutations in MSI colorectal tumors and aberrant methylation of the regulatory sequences of this important tumor suppressor gene.
|
16288001 |
2005 |
|
Colorectal Neoplasms
|
0.190 |
AlteredExpression
|
group |
LHGDN |
EphB receptor activity suppresses colorectal cancer progression.
|
15973414 |
2005 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
BEFREE |
Taking advantage of this polymorphism within EPHB2, we surveyed the loss of heterozygosity (LOH) status of this gene in Japanese colorectal tumors.
|
11166921 |
2001 |
|
Central Nervous System Neoplasms
|
0.110 |
Biomarker
|
group |
BEFREE |
Recent studies highlight the importance of BRAF alterations resulting in mitogen activated protein kinase (MAK/ERK) pathway activation in low-grade CNS tumors.
|
22157620 |
2012 |
|
Central Nervous System Neoplasms
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upregulated expression of P-gp mRNA and efflux potential of P-gp were inhibited by TAK1 or ERK inhibitors in RA peripheral blood lymphocytes.
|
31376257 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC.
|
31634668 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib.
|
31821539 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of NSCLC with LukS-PV combined with p38 and ERK inhibitors reversed the pro-apoptotic and pro-cell cycle arrest effects of LukS-PV.
|
31708104 |
2020 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, VPS33B as a tumor suppressor is easily dysregulated by chemical carcinogens and it interacts with NESG1 to modulate the EGFR/RAS/ERK/c-Myc/p53/miR-133a-3p feedback loop and thus suppress the malignant phenotype of CRC.
|
31125123 |
2020 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.
|
31776900 |
2020 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings showed that KCNN4 promotes HCC invasion and metastasis through the MAPK/ERK pathway.
|
31431469 |
2020 |